Rhythm Pharmaceuticals amends LG Chem deal with $350m payments
Rhythm Pharmaceuticals has renegotiated the terms of its global exclusive licence with South Korea's LG Chem for bivamelagon, an investigational oral melanocortin-4 receptor (MC4R) agonist, replacing a tiered royalty structure with fixed cash instalments and a simplified ongoing royalty rate. To fund the restructured arrangement, the Boston-based company has simultaneously secured a $750 million term-loan facility co-led by KKR's HealthCare Royalty and Blackstone.
Under the amended licence, Rhythm will pay LG Chem $350 million across four tranches over the next three years: $70 million on or around 2 November 2026, followed by $100 million in September 2027, $100 million in September 2028, and $80 million in September 2029. The sliding royalty in the original January 2024 agreement, which ranged from low-to-mid-single digits depending on the number of approved indications, has been replaced with a flat 1% royalty on global net sales of all products in Rhythm's MC4R portfolio from 1 January 2029, or from the date of bivamelagon's first commercial sale if that comes earlier. A new sales-linked milestone of up to $200 million has also been added, triggered on achieving $3 billion in annual global net sales across the MC4R portfolio.
The financing structure
The $750 million, five-year term-loan facility has $500 million of committed capital. An initial $250 million draw is expected to close on 6 November 2026. A further $250 million of committed delayed-draw capital is available in three tranches through June 2028, with an additional $250 million accessible by mutual consent. Borrowings carry an interest rate of SOFR plus 4.60%, with no scheduled amortisation before maturity and no equity dilution. Rhythm said the deal also modifies its pre-existing revenue-interest financing agreement with HealthCare Royalty, removing debt-like covenants and limiting collateral.
David Meeker, chairman, president and chief executive of Rhythm, said bivamelagon "has been shown to achieve clinically meaningful weight loss in patients living with acquired hypothalamic obesity," describing the amendment as a reflection of confidence in the asset's long-term commercial potential.
Market context and competitive landscape
Rhythm's existing approved product, setmelanotide (IMCIVREE), is already authorised by the FDA, the European Commission and the UK's MHRA for several rare MC4R pathway diseases including Bardet-Biedl syndrome and acquired hypothalamic obesity. Bivamelagon represents the first oral candidate in this mechanistic class, which is significant given that setmelanotide is administered by daily subcutaneous injection. An oral MC4R agonist could meaningfully expand the addressable patient population and ease adherence burdens.
The rare-obesity space has attracted growing interest from larger pharma groups, with the GLP-1 receptor agonist wave prompting companies to look for differentiated positioning in genetically defined obesity sub-populations where peptide-based therapies may have limited efficacy. Rhythm's strategy of building a portfolio of MC4R agonists across multiple rare indications is designed to give it defensible niche positioning, though the $3 billion annual sales milestone embedded in the amended deal underscores the scale of commercial ambition the company is projecting for the asset class.
The financing structure, involving specialist royalty capital rather than conventional equity or convertible debt, reflects a maturing trend in rare-disease biotech funding. Royalty-backed lending allows companies to preserve equity while monetising anticipated future commercial revenues. For investors, the key near-term milestones will be Phase 3 data readouts for bivamelagon in acquired hypothalamic obesity, regulatory submissions, and the pace of setmelanotide uptake as an indicator of the commercial infrastructure Rhythm is building to support a broader MC4R franchise.